Clinical Meaningfulness of Biomarker Endpoints in Alzheimer’s Disease Research

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-4939-7674-4_16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

  2019cited by this paper
• Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

  2017cited by this paper
• The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

  2017cited by this paper
• Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

  2017cited by this paper
• F4‐03‐02: The Dominantly Inherited Alzheimer Network Trials Unit

  2016cited by this paper
• F4‐03‐03: Anti‐Amyloid Treatment of Asymptomatic Ad: A4 and Beyond

  2016cited by this paper
• Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

  2016cited by this paper
• Tau positron emission tomographic imaging in aging and early Alzheimer disease

  2016cited by this paper
• A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

  2016cited by this paper
• Clinical Impact of Amyloid Positron Emission Tomography-Is It Worth the Cost?

  2016cited by this paper
• 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease

  2016cited by this paper
• Understanding the Functional Plasticity in Neural Networks of the Basal Ganglia in Cocaine Use Disorder: A Role for Allosteric Receptor-Receptor Interactions in A2A-D2 Heteroreceptor Complexes

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

  2016cited by this paper
• Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease

  2016cited by this paper
• Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

  2016cited by this paper
• Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  2016cited by this paper
• Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

  2015cited by this paper
• Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

  2015cited by this paper
• Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease

  2015cited by this paper
• Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

  2015cited by this paper
• Anti-tau antibody reduces insoluble tau and decreases brain atrophy

  2015cited by this paper
• Tau imaging: early progress and future directions.

  2015cited by this paper
• O4‐07‐01: T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a

  2015cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

  2014cited by this paper
• Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues

  2014cited by this paper
• A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.

  2013cited by this paper
• Using AD biomarker research results for clinical care

  2013cited by this paper
• Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.

  2013cited by this paper
• Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies

  2013cited by this paper
• Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

  2013cited by this paper
• Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

  2013cited by this paper
• How can elderly apolipoprotein E ε4 carriers remain free from dementia?

  2013cited by this paper
• Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education

  2013cited by this paper
• Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

  2013cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• World Alzheimer Report 2012: Overcoming the Stigma of Dementia

  2012cited by this paper
• Modifiable factors that alter the size of the hippocampus with ageing

  2012cited by this paper
• Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

  2012cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

  2012cited by this paper
• In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.

  2011cited by this paper
• Neuropathological alterations in Alzheimer disease.

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease

  2011cited by this paper
• Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications

  2011cited by this paper
• A tribute to the Extramural Epidemiology Program, National Institute on Aging

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

  2010cited by this paper
• Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

  2010cited by this paper
• Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging

  2010cited by this paper
• The clinical use of structural MRI in Alzheimer disease

  2010cited by this paper
• Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

  2009cited by this paper
• Conversion of amyloid positive and negative MCI to AD over 3 years

  2009cited by this paper
• Disclosure of APOE genotype for risk of Alzheimer's disease.

  2009cited by this paper
• Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

  2009cited by this paper
• Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

  2008cited by this paper
• Apolipoprotein E ε4 magnifies lifestyle risks for dementia: a population-based study

  2008cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

  2007cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury

  2006cited by this paper
• CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

  2003cited by this paper
• Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

  2003cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.

  2002cited by this paper
• Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia.

  2001cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis

  1997cited by this paper
• Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

  1997cited by this paper
• Staging of Alzheimer's disease-related neurofibrillary changes.

  1995cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper

• Ethical and Social Implications of Using Predictive Modeling for Alzheimer’s Disease Prevention: A Systematic Literature Review

  2020influential citation